The agreement outlines the terms of cooperation and collaboration between the parties to establish a corporate R&D center for innovative drug development by the Pharmasyntez Group on the territory of the Skolkovo Innovation Center.

By signing this agreement, Pharmasyntez, as the leading supplier of its medicines to the country’s healthcare institutions, reaffirms its strategic goal — to transition from a generics-based business model to an innovative development model. The parties also agreed to collaborate in creating technological leaders in the pharmaceutical industry.

Pharmasyntez is planning to build a world-class R&D center for new drug development on the Skolkovo territory within the next three years, with research laboratories spanning 5,000 square meters. The Pharmasyntez Group headquarters will be located in this R&D center building.

Vikram Punia remarked:

“Recognizing that the only path to significant company growth is the development and production of innovative drugs, Pharmasyntez has made a strategic decision to focus exclusively on creating domestically developed pharmaceuticals. The best platform for realizing this ambitious task today is Skolkovo — a unique innovation cluster with all the necessary infrastructure for comfortable and efficient work.
We aim to complete the implementation of our project by the end of 2028. As part of this plan, the construction of a modern center for innovative drug development, spanning over 5,000 square meters, is scheduled. The total infrastructure of the complex will exceed 15,000 square meters, providing all the conditions to achieve our goals and create cutting-edge solutions in pharmaceuticals.